Therapeutic peptides targeting PPI in clinical development: Overview, mechanism of action and perspectives

W Cabri, P Cantelmi, D Corbisiero, T Fantoni… - Frontiers in Molecular …, 2021 - frontiersin.org
Targeting protein-protein interactions (PPIs) has been recently recognized as an emerging
therapeutic approach for several diseases. Up today, more than half a million PPI …

Antioxidants in translational medicine

HHHW Schmidt, R Stocker, C Vollbracht… - Antioxidants & redox …, 2015 - liebertpub.com
Significance: It is generally accepted that reactive oxygen species (ROS) scavenging
molecules or antioxidants exert health-promoting effects and thus their consumption as food …

Immunity and inflammation in pulmonary arterial hypertension: from pathophysiology mechanisms to treatment perspective

R Wang, T Yuan, J Wang, Y Chen, J Zhao, M Li… - Pharmacological …, 2022 - Elsevier
Pulmonary arterial hypertension (PAH) is a severe cardiopulmonary dysfunctional disease,
characterized by progressive vascular remodeling. Inflammation is an increasingly …

Structural and biochemical characterization establishes a detailed understanding of KEAP1-CUL3 complex assembly

RJ Adamson, NC Payne, SG Bartual… - Free Radical Biology …, 2023 - Elsevier
KEAP1 promotes the ubiquitin-dependent degradation of NRF2 by assembling into a CUL3-
dependent ubiquitin ligase complex. Oxidative and electrophilic stress inhibit KEAP1 …

Mitochondrial dysfunction and pulmonary hypertension: cause, effect, or both

JD Marshall, I Bazan, Y Zhang… - American Journal of …, 2018 - journals.physiology.org
Pulmonary hypertension describes a heterogeneous disease defined by increased
pulmonary artery pressures, and progressive increase in pulmonary vascular resistance due …

A small molecule inhibits deregulated NRF2 transcriptional activity in cancer

MJ Bollong, H Yun, L Sherwood, AK Woods… - ACS chemical …, 2015 - ACS Publications
NRF2 serves as the master regulator of oxidative stress resistance in mammalian cells.
Although NRF2 activation decreases tumorigenic events in normal cells, accumulating …

mTOR signaling in pulmonary vascular disease: pathogenic role and therapeutic target

A Babicheva, A Makino, JXJ Yuan - International journal of molecular …, 2021 - mdpi.com
Pulmonary arterial hypertension (PAH) is a progressive and fatal disease without a cure.
The exact pathogenic mechanisms of PAH are complex and poorly understood, yet a …

Therapeutic effects of Nrf2 activation by bardoxolone methyl in chronic heart failure

C Tian, L Gao, A Zhang, BT Hackfort… - Journal of Pharmacology …, 2019 - ASPET
Oxidative stress plays an important role in the pathogenesis of chronic heart failure (CHF) in
many tissues. Increasing evidence suggests that systemic activation of nuclear factor …

Identification of celastramycin as a novel therapeutic agent for pulmonary arterial hypertension: high-throughput screening of 5562 compounds

R Kurosawa, K Satoh, N Kikuchi, H Kikuchi… - Circulation …, 2019 - Am Heart Assoc
Rationale: Pulmonary arterial hypertension (PAH) is characterized by enhanced proliferation
of pulmonary artery smooth muscle cells (PASMCs) accompanying increased production of …

Cytokines, chemokines, and inflammation in pulmonary arterial hypertension

S Liang, AA Desai, SM Black, H Tang - … in Health and Disease, Volume I, 2021 - Springer
Abstract According to the World Symposium Pulmonary Hypertension (WSPH) classification,
pulmonary hypertension (PH) is classified into five categories based on etiology. Among …